Today, we want to share our analysis of Agenus (AGEN) with you. Over the last year, its stock fluctuated largely, falling from ~$3.67 in January 2019 to ~$2.6 in August 2019. Recently, the company’s stock price grew by over 15%, driven by the IND acceptance for AGEN2373. The company has a number of attractive catalysts moving forward. So, let’s dig in!
Company description
Agenus is a clinical-stage biotechnology company that concentrates on developing treatments for cancer. The company, based in Lexington, MA, was founded in 1994 and went public in February 2000,